Next Article in Journal
Recent Developments in the Suzuki-Miyaura Reaction: 2010–2014
Previous Article in Journal
Synthesis and 11C-Radiolabelling of 2-Carboranyl Benzothiazoles
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(5), 7509-7527;

Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers

Division of Regulatory Glycobiology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aobaku, Sendai, Miyagi 981-8558, Japan
Authors to whom correspondence should be addressed.
Academic Editor: Derek J. McPhee
Received: 19 March 2015 / Revised: 17 April 2015 / Accepted: 22 April 2015 / Published: 24 April 2015
(This article belongs to the Section Medicinal Chemistry)
Full-Text   |   PDF [892 KB, uploaded 24 April 2015]   |  


Altered glycosylation is a common feature of cancer cells. It takes a variety of forms, which includes loss of expression or excessive expression of some structures, the accumulation of precursors, the appearance of novel structures, etc. Notably, these changes in glycan structure do not occur as a random consequence of disorder biology. Only a limited subset of oligosaccharides is found frequently enriched on the tumor cell surface and implicated in different tumor phenotypes. Among these, altered sialylation has long been associated with metastatic cell behaviors such as invasion and enhanced cell survival and accumulating evidence points to the alteration occurring in the sialic acid linkage to other sugars, which normally exists in three main configurations: α2,3, α2,6, and α2,8, catalyzed by a group of sialyltransferases. The aberrant expression of all three configurations has been described in cancer progression. However, the increased α2,6 sialylation catalyzed by β-galactoside α2,6 sialyltranferase 1 (ST6Gal I) is frequently observed in many types of the cancers. In this review, we describe the findings on the role of ST6Gal I in cancer progression, and highlight in particular the knowledge of how ST6Gal I-mediated α2,6 sialylated glycans or sialylated carrier proteins regulate cell signaling to promote the malignant phenotype of human carcinoma. View Full-Text
Keywords: cancer metastasis; sialylation; ST6Gal I cancer metastasis; sialylation; ST6Gal I

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lu, J.; Gu, J. Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers. Molecules 2015, 20, 7509-7527.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top